The effect of DC+CIK combined therapy on rat liver cancer model and its modulatory effect on immune functions

Primary liver cancer is a sort of the most common solid tumors occurred in the digestive system. The incidence and mortality rate maintain at a high level, thus leading to heavy economic and psychological burdens for patients. Next-generation biological therapy, such as cellular immune treatment, improves the medicine efficacy. Cytokine-induced killer (CIK) cells can effectively clear residual tumor lesion and inhibit metastasis or recurrence. Dendritic cells (DCs) can specifically eliminate tumor cells via modulating cellular immune function of the host. This study aimed to investigate the function of DC+CIK combined treatment on rat liver model and its effect on immune functions.

RH-35 tumor cell was used to prepare live cancer model on Wistar rats, which were further divided into control, CIK and DC+CIK groups, in which rats received autograft CIK and DCs. Tumor size was later measured along with liver function index. The secretions of IFN-γ, IL-4, and TNF-α were measured by Real-time PCR and Western blotting.

Both CIK and DC+CIK treatment significantly reduced tumor size and improved liver function, increased secretion of IFN-γ, IL-4, and TNF-α, decreased Bcl-2 expression and enhanced Bax expression (p < 0.05 compared to control group). DC+CIK combined therapy presented significantly better efficacy than CIK did.

DC+CIK combined therapy can protect the host against tumors invasion via modulating body immune or liver function, regulating apoptosis/anti-apoptosis balance, which shows better efficacy than CIK alone, and can work as a novel biological therapeutic strategy for liver cancer.